All 1 Yvette Cooper contributions to the Coronavirus Act 2020

Read Bill Ministerial Extracts

Mon 23rd Mar 2020
Coronavirus Bill
Commons Chamber

2nd reading & 2nd reading & 2nd reading: House of Commons & 2nd reading

Coronavirus Bill

Yvette Cooper Excerpts
2nd reading & 2nd reading: House of Commons
Monday 23rd March 2020

(4 years, 8 months ago)

Commons Chamber
Read Full debate Coronavirus Act 2020 Read Hansard Text Read Debate Ministerial Extracts Amendment Paper: Committee of the whole House Amendments as at 23 March 2020 - (23 Mar 2020)
Matt Hancock Portrait Matt Hancock
- Hansard - - - Excerpts

It is already within NHS trusts’ power to pay those visa fees if it is necessary.

Yvette Cooper Portrait Yvette Cooper (Normanton, Pontefract and Castleford) (Lab)
- Hansard - -

Will the Secretary of State look at the immigration surcharge for doctors and nurses who are working in intensive care units? Will he also look personally at the issues relating to research trials for potential new drugs or treatments, or existing drugs or treatments that are being used? Concerns have been raised with me that those processes are all being delayed by the traditional randomised controlled trial processes, which may not be appropriate given the emergency we face.

Matt Hancock Portrait Matt Hancock
- Hansard - - - Excerpts

Absolutely. The chief medical officer is personally looking into that issue to make sure that when there is a treatment, we can bring it to bear as soon as is safely possible. There is a challenge with a disease that has, thankfully, a mortality rate as a proportion of the overall population as low as this one, which is that we do not want to do more harm than good. Many of these drugs are safe, because they are licensed for another purpose. It is a question of repurposing them—this is for treatment, rather than vaccine—and that is something we are actively working on. If the right hon. Lady has examples of particular barriers that we need to crunch through I would like to know about them. If she could email me I will take that up with the Medicines and Healthcare Products Regulatory Agency.